Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 15/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1730517 | 0.99 | F2R (0.52) | F2RHCRTR2 | |
| Bromide SCHEMBL1732143 | 0.92 | F2R (0.56) | F2R | |
| Bromide SCHEMBL5484855 | 0.91 | F2R (0.60) | F2RSTING1 | |
| Bromide SCHEMBL5485994 | 0.89 | F2R (0.59) | F2RSTING1 | |
| Bromide SCHEMBL5490749 | 0.88 | F2R (0.53) | F2RHCRTR2STING1 | |
| Bromide SCHEMBL1730541 | 0.87 | F2R (0.52) | F2RHCRTR2STING1 | |
| Bromide SCHEMBL1732011 | 0.86 | F2R (0.58) | F2RSTING1 | |
| Bromide SCHEMBL1730033 | 0.86 | F2R (0.68) | F2RSTING1 | |
| Bromide SCHEMBL1729924 | 0.85 | F2R (0.55) | F2R | |
| Bromide SCHEMBL1732080 | 0.85 | F2R (0.56) | F2RSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973407-B1 | SPIRO COMPOUNDS AND METHODS OF USE | CHEN GUOQING PAUL (US) | 2011-11-23 | — | — | EP | claimed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2290/4885HCRTR2 141/4885STING1 4502/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2289/4885HCRTR2 149/4885STING1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.